Evidence map›Paper›PMID 38930831›Full record

ArticleMolecules (Basel, Switzerland)2024

Conjugates of 3,5-Bis(arylidene)-4-piperidone and Sesquiterpene Lactones Have an Antitumor Effect via Resetting the Metabolic Phenotype of Cancer Cells.

M E Neganova, Yu R Aleksandrova, E V Sharova, E V Smirnova, O I Artyushin, N S Nikolaeva, A V Semakov, I A Schagina, N Akylbekov, R Kurmanbayev and 2 more

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Plant-Derived Anti-Cancer Therapeutics and Biopharmaceuticals.Bioengineering (Basel, Switzerland) · 2024
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

M E NeganovaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 142432 Chernogolovka, Russia.ORCID 0000-0001-9346-5920
Yu R AleksandrovaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 142432 Chernogolovka, Russia.ORCID 0000-0002-5370-3370
E V SharovaNesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 119991 Moscow, Russia.
E V SmirnovaNesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 119991 Moscow, Russia.
O I ArtyushinNesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 119991 Moscow, Russia.
N S NikolaevaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 142432 Chernogolovka, Russia.
A V SemakovInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 142432 Chernogolovka, Russia.ORCID 0000-0002-6434-8976
I A SchaginaInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 142432 Chernogolovka, Russia.
N AkylbekovLaboratory of Engineering Profile "Physical and Chemical Methods of Analysis", Korkyt Ata Kyzylorda University, Aiteke bi Str. 29A, 120014 Kyzylorda, Kazakhstan.ORCID 0000-0002-7584-9741
R KurmanbayevLaboratory of Engineering Profile "Physical and Chemical Methods of Analysis", Korkyt Ata Kyzylorda University, Aiteke bi Str. 29A, 120014 Kyzylorda, Kazakhstan.
D OrynbekovLaboratory of Engineering Profile "Physical and Chemical Methods of Analysis", Korkyt Ata Kyzylorda University, Aiteke bi Str. 29A, 120014 Kyzylorda, Kazakhstan.
V K BrelNesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 119991 Moscow, Russia.

Funding

the Non-Profit Joint-Stock Company "Korkyt Ata Kyzylorda University" the Non-Profit Joint-Stock Company "Korkyt Ata Kyzylorda University"
6 · The paper itself

Abstract

In recent years, researchers have often encountered the significance of the aberrant metabolism of tumor cells in the pathogenesis of malignant neoplasms. This phenomenon, known as the Warburg effect, provides a number of advantages in the survival of neoplastic cells, and its application is considered a potential strategy in the search for antitumor agents. With the aim of developing a promising platform for designing antitumor therapeutics, we synthesized a library of conjugates of 3,5-bis(arylidene)-4-piperidone and sesquiterpene lactones. To gain insight into the determinants of the biological activity of the prepared compounds, we showed that the conjugates of 3,5-bis(arylidene)-4-piperidone and sesquiterpene lactones, which are cytotoxic agents, demonstrate selective activity toward a number of tumor cell lines with glycolysis-inhibiting ability. Moreover, the results of molecular and in silico screening allowed us to identify these compounds as potential inhibitors of the pyruvate kinase M2 oncoprotein, which is the rate-determining enzyme of glycolysis. Thus, the results of our work indicate that the synthesized conjugates of 3,5-bis(arylidene)-4-piperidone and sesquiterpene lactones can be considered a promising platform for designing selective cytotoxic agents against the glycolysis process, which opens new possibilities for researchers involved in the search for antitumor therapeutics among compounds containing piperidone platforms.

Indexed as

Antineoplastic AgentsLactonesPiperidonesSesquiterpenesCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorGlycolysisHumansMolecular Docking SimulationNeoplasmsAntineoplastic AgentsLactonesPiperidonesSesquiterpenes3,5-bis(arylidene)-4-piperidoneacetylenesalantolactoneazidesclick chemistrycytotoxicitydehydrocostuslactoneglycolysissesquiterpene lactones

Identifiers

PMID38930831
PMCPMC11207066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.